Tenderwize
Zurück zur Suche

Open House Discount Contracts for Omalizumab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 187 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Omalizumab, ATC R03DX05

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

30 / 100

Komplexität

20 / 100

Risikofaktoren

No indication of expected sales volume or number of patients; the discount may not generate significant revenue.

The buyer may replace open house contracts with exclusive ones from a separate tender, automatically ending all open ho...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount contracts (Rabattverträge) under German Social Code (§§ 130a Abs. 8/130c Abs. 1 SGB V) for Omalizumab.
  • Contracts are open to all pharmaceutical companies that supply authorized and marketable Omalizumab products in Germany.
Vollständige Zusammenfassung anzeigen

Open house (non-exclusive) discount contracts for pharmaceutical products containing the active substance Omalizumab (ATC R03DX05), offered by AOK Rheinland-Pfalz/Saarland. The model allows any interested pharmaceutical company to enter into a standard agreement at any time during the 24-month period (May 2025 – April 2027). No competitive selection; all qualified applicants are accepted. The first contracts start 1 May 2025; initial application deadline is 31 March 2025. Later enrollments are possible monthly. The buyer may replace these non-exclusive contracts with exclusive ones during the term. The notice is published voluntarily for transparency; it is not a public procurement under EU directives.

Risiken

No indication of expected sales volume or number of patients; the discount may not generate significant revenue.

The buyer may replace open house contracts with exclusive ones from a separate tender, automatically ending all open ho...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Provide authorized and marketable Omalizumab products in Germany (proof via Lauer-Taxe listing or AMIce database extracts).

Administrative

  • Submit signed contract documents and required annexes by applicable deadline.
  • No electronic submission; paper documents required (original by mail or courier).

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria defined; all eligible participants are accepted.

Auftraggeber

Lose (1)

LOT-0001

Open House Discount Contracts for Omalizumab

Non-exclusive framework discount contracts for Omalizumab (ATC R03DX05). All pharmaceutical companies with authorized and marketable products in Germany can join. Standard terms, no negotiation. Max duration 24 months from earliest start (May 2025). Contracts end automatically if replaced by exclusive contracts from a separate tender.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria defined; all eligible participants are accepted.

Frist

Deadline Feb 28, 2027

Vergabedetails

Veröffentlichungsdatum
12 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
163311-2025

Dokumente (1)

Ähnliche Ausschreibungen